Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial

DJ Khalaf; CK Kollmannsberger; BJ Eigl; K Noonan; D Wadhwa; A Attwell; B Keith; SL Ellard; L Le; ME Gleave; AW Wyatt; M Annala; KN Chi; S Taavitsainen; DL Finch; C Oja; J Vergidis; M Zulfiqar; K Sunderland; AA Azad

doi:10.1016/S1470-2045(19)30688-6

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial

DJ Khalaf, CK Kollmannsberger, BJ Eigl, K Noonan, D Wadhwa, A Attwell, B Keith, SL Ellard, L Le, ME Gleave, AW Wyatt, M Annala, KN Chi, S Taavitsainen, DL Finch, C Oja, J Vergidis, M Zulfiqar, K Sunderland, AA Azad

Research output: Contribution to journal › Article › Scientific › peer-review

265 Citations (Scopus)

Original language	English
Pages (from-to)	p1730-1739
Journal	The Lancet Oncology
Volume	20
Issue number	12
DOIs	https://doi.org/10.1016/S1470-2045(19)30688-6
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 3

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(19)30688-6

http://urn.fi/URN:NBN:fi:tuni-201912166909

Cite this

Khalaf, DJ., Kollmannsberger, CK., Eigl, BJ., Noonan, K., Wadhwa, D., Attwell, A., Keith, B., Ellard, SL., Le, L., Gleave, ME., Wyatt, AW., Annala, M., Chi, KN., Taavitsainen, S., Finch, DL., Oja, C., Vergidis, J., Zulfiqar, M., Sunderland, K., & Azad, AA. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology, 20(12), p1730-1739. https://doi.org/10.1016/S1470-2045(19)30688-6

@article{717f589de68542478e131ef753d6a138,

title = "Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial",

author = "DJ Khalaf and CK Kollmannsberger and BJ Eigl and K Noonan and D Wadhwa and A Attwell and B Keith and SL Ellard and L Le and ME Gleave and AW Wyatt and M Annala and KN Chi and S Taavitsainen and DL Finch and C Oja and J Vergidis and M Zulfiqar and K Sunderland and AA Azad",

year = "2019",

doi = "10.1016/S1470-2045(19)30688-6",

language = "English",

volume = "20",

pages = "p1730--1739",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "12",

}

Khalaf, DJ, Kollmannsberger, CK, Eigl, BJ, Noonan, K, Wadhwa, D, Attwell, A, Keith, B, Ellard, SL, Le, L, Gleave, ME, Wyatt, AW, Annala, M, Chi, KN, Taavitsainen, S, Finch, DL, Oja, C, Vergidis, J, Zulfiqar, M, Sunderland, K & Azad, AA 2019, 'Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial', The Lancet Oncology, vol. 20, no. 12, pp. p1730-1739. https://doi.org/10.1016/S1470-2045(19)30688-6

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial. / Khalaf, DJ; Kollmannsberger, CK; Eigl, BJ et al.
In: The Lancet Oncology, Vol. 20, No. 12, 2019, p. p1730-1739.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial

AU - Khalaf, DJ

AU - Kollmannsberger, CK

AU - Eigl, BJ

AU - Noonan, K

AU - Wadhwa, D

AU - Attwell, A

AU - Keith, B

AU - Ellard, SL

AU - Le, L

AU - Gleave, ME

AU - Wyatt, AW

AU - Annala, M

AU - Chi, KN

AU - Taavitsainen, S

AU - Finch, DL

AU - Oja, C

AU - Vergidis, J

AU - Zulfiqar, M

AU - Sunderland, K

AU - Azad, AA

PY - 2019

Y1 - 2019

U2 - 10.1016/S1470-2045(19)30688-6

DO - 10.1016/S1470-2045(19)30688-6

M3 - Article

SN - 1470-2045

VL - 20

SP - p1730-1739

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 12

ER -